Alliance Entertainment (Nasdaq: AENT) has closed a new 5-year, $120 million senior secured revolving credit facility with Bank of America, replacing its previous ABL structure. The new agreement strengthens the company’s capital position with an initial interest rate 250 basis points lower than the previous facility, supporting continued growth across its expansive entertainment and collectibles distribution network.

BullFrog AI (Nasdaq: BFRG) has expanded its internal sales force to accelerate the commercial rollout of its clinical trial optimization tools, including the recently launched bfPREP™ module. The move strengthens the company’s go-to-market capabilities alongside its Sygnature Discovery partnership and positions BullFrog AI to meet rising demand for AI-driven solutions that reduce risk and cost in drug development.

Connect Biopharma (Nasdaq: CNTB) presented compelling new data at the European Respiratory Society Congress showing that rademikibart delivered rapid, significant improvements in lung function and asthma control, especially in patients with elevated Type 2 inflammatory biomarkers. With reductions of up to 69% in annualized exacerbations, the findings bolster confidence in ongoing Phase 2 Seabreeze STAT trials for asthma and COPD, with topline results expected in the first half of 2026.

Bimergen Energy (OTCQB: BESS) has secured a $50 million capital commitment to accelerate the development of up to 2 GW of utility-scale battery energy storage projects through 2027. With the first $10 million tranche received, the funding enables procurement of long-lead items uand positions Bimergen to capitalize on strong tailwinds from federal tax incentives and surging AI-driven energy demand.